CD40LG and neuropathy: Although the efficacy of IVIg in IgM paraproteinemic neuropathies is not well established, the levels of IgM myelin-associated glycoprotein (MAG) and sulfoglucuronyl paragloboside (SGPG) antibodies are reduced in occasional patients treated with this therapy [15].